HIV Virology Core

HIV病毒学核心 支持三个PCHPI项目的需求，合作发展奖的获得者，以及外部 在合作项目中，我们将建立一个艾滋病毒学核心（HVC）。HVC的主要任务是 测试由中心项目产生的新结构信息产生的假设，并推动研究 补充项目说明中详述的拟议结构工程。HVC将 通过使用一系列检测和贸易工具对HIV-1进行功能研究来实现这些目标。 由经验丰富的研究人员领导的三个小组将为这项工作做出贡献：Chris Aiken（专门从事分析 HIV-1复制; HIV-1核心的纯化和分析; HIV-1突变体的功能研究; 内源性逆转录）; AlanEngelman（专门从事HIV-1整合的功能研究， 包括整合位点的深度测序分析;基因敲除和重新编码敲入实验， 分析细胞突变对HIV-1感染的影响，重点是核进入和整合缺陷; 通过透射电子显微镜定量评估病毒体形态; 人细胞培养物）;和Zandrea Ambrose（专门从事单周期感染测定; 单颗粒未包被; HIV-1感染缺陷的分期;以及HIV-1侵入的基于细胞的成像研究， 包括细胞内运输、运输蛋白的基因敲低/敲除以及原发性 细胞）。HVC将由Aiken和Engelman共同管理，这一安排为 PCHPI良好，并将确保项目得到适当的支持。

HIV Virology Core To support the needs of the three PCHPI projects, recipients of Collaborative Development Awards, and external collaborative projects, we will establish an HIV Virology Core (HVC). The primary missons of the HVC will be to test hypotheses resulting from new structural information generated by the center projects and to drive studies that are complementary to the proposed structural work, as detailed in the project descriptions. The HVC will achieve these goals by performing functional studies of HIV-1 using a battery of assays and tools of the trade. Three groups, led by experienced investigators, will contribute to the effort: Chris Aiken (specializing in assays of HIV-1 replication; purification and analysis of HIV-1 cores; functional studies of HIV-1 mutants; and assays of endogenous reverse transcription); Alan Engelman (specializing in functional studies of HIV-1 integration, including deep sequencing analysis of integration sites; gene knock-out and recoding knock-in experiments to anlyze effects of cell mutations on HIV-1 infection, with an emphasis on nuclear entry and integration defects; quantitative assessment of virion morphology by transmission electron microscopy; and work with primary human cell cultures); and Zandrea Ambrose (specializing in single-cycle infection assays; in vitro analysis of single-particle uncoating; staging of HIV-1 infection defects; and cell-based imaging studies of HIV-1 ingress, including intracellular trafficking, gene knockdown/knockout of trafficking proteins, and infections of primary cells). The HVC will be collaboratively managed by Aiken and Engelman, an arrangement that has served the PCHPI well and will ensure that the Projects are appropriately supported.